BioPharmSignal logoBioPharmSignal

Biotech News

Theravance Biopharma to Participate in Upcoming Investor Conferences

Theravance Biopharma (TBPH)Theravance BiopharmaConference / presentation

DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025 : 8 th Annual Evercore Healthcare Conference Location: Coral Gables, FL Format: Fireside Chat Date: Thursday,

Related news

TBPHTheravance Biopharma2025-09-02 10:00 EST

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

RVPHReviva Pharmaceuticals2025-10-29 12:00 EST

Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference

RVPHReviva Pharmaceuticals2025-09-23 12:00 EST

Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference

VERUVeru Inc2026-07-30 12:30 EST

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

XAIRBeyond Air2026-04-15 12:00 EST

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

XAIRBeyond Air2026-03-11 11:00 EST

Beyond Air to Participate in the 38th Annual Roth Conference in March

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

SVRASavara, Inc.2018-11-16 13:00 EST

Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th

INSMInsmed2026-05-27 11:00 EST

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

View all latest news

Theravance Biopharma

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Stock data

Close
16.92 USD
Market cap
803.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States